Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARO ROLL OVER: Continued Darolutamide Treatment in Cancer Patients
NCT04464226Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Oct 2020
- Primary completion
- Jun 2028
- Modality
- Orthosteric Ligands
- Countries
- 39
01
Overview
A Phase 3 trial of darolutamide in cancer, sponsored by Bayer. Started Oct 2020; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04464226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464226.